Immunovant earnings were -$323.0M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest IMVT earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$111.1M, up 1.8% from last quarter. For the last reported fiscal year 2024 ending Mar 31, 2024, IMVT reported annual earnings of -$259.3M, with 22.9% growth. The next IMVT earnings date is Feb 10, 2025.
On IMVT's earnings call on Invalid Date, Immunovant (NASDAQ: IMVT) reported Q4 2024 earnings per share (EPS) of -$0.76, up 111.11% year over year. Total IMVT earnings for the quarter were -$111.12 million. In the same quarter last year, Immunovant's earnings per share (EPS) was -$0.36.
The next IMVT earnings call is Invalid Date. Add IMVT to your watchlist to be reminded of Immunovant's next earnings date.
Is Immunovant profitable or losing money?
As of the last Immunovant earnings report, Immunovant is currently losing money. Immunovant's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$382.71 million, a 57.2% increase year over year.
What was IMVT's earnings growth in the past year?
As of Immunovant's earnings date in Invalid Date, Immunovant's earnings has grown year over year. IMVT earnings in the past year totalled -$323.01 million.
What are Immunovant's earnings expectations?
The current EPS estimate for Immunovant's earnings report in Invalid Date is -$0.75.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.